<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="49521">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02461537</url>
  </required_header>
  <id_info>
    <org_study_id>DKMS-14-01</org_study_id>
    <secondary_id>2014-003124-44</secondary_id>
    <nct_id>NCT02461537</nct_id>
  </id_info>
  <brief_title>Impact of Remission Induction Chemotherapy Prior to Allogeneic SCT in Relapsed and Poor-response Patients With AML (ETAL3-ASAP)</brief_title>
  <official_title>Evaluation of the Impact of Remission Induction Chemotherapy Prior to Allogeneic Stem Cell Transplantation in Relapsed and Poor-response Patients With AML</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>DKMS gemeinnützige GmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>DKMS gemeinnützige GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial compares outcome of two treatment strategies for patients with high-risk AML who
      failed to achieve or maintain a complete remission with standard therapy. Patients will be
      randomized between two strategies. The standard strategy is aimed at achieving a complete
      remission by aggressive salvage chemotherapy using high dose cytarabine and mitoxantrone, .
      The alternative is a less toxic disease-control strategy of disease monitoring and, if
      necessary, low-dose cytarabine or mitoxantrone prior to allogeneic transplantation, which
      should be performed as soon as possible.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with high-risk acute myeloid leukemia (AML) who relapsed or showed a poor response
      to induction chemotherapy have a dismal prognosis. For these patients, allogeneic
      transplantation is the recommended treatment. While allogeneic transplantation may be
      considered as the ultimate treatment concept, the treatment path to transplantation is not
      well defined.

      The traditional approach to pursue a complete remission by means of aggressive reinduction
      chemotherapy prior to allogeneic transplantation. This approach is associated with
      potentially life-threatening toxicities and has limited efficacy. As a result, only some
      patients will reach allogeneic transplantation in complete remission.

      To reduce the number of patients who die or who are ineligible for transplantation due to
      the toxicity of aggressive induction chemotherapy, other bridging options have been
      explored. One promising alternative is to abstain from remission induction. Instead, disease
      control by means of less aggressive chemotherapy or simply monitoring leukemic proliferation
      can be considered.

      This randomized trial will identify if there is non-inferiority of the less toxic approach,
      compared to the standard approach of remission induction by aggressive chemotherapy prior to
      allogeneic transplantation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>on day 56 after allogeneic SCT</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>4 weeks, 8 weeks, and 24 weeks from randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of allogeneic transplantation</measure>
    <time_frame>4 weeks, 8 weeks, and 16 weeks from randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of CR</measure>
    <time_frame>at 4 weeks, 8 weeks, and 24 weeks from randomization</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">308</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>RIST(remission induction)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>high-dose cytarabine 3 g/m2 (days 1-3)/mitoxantrone 10mg/m2 (days 3-5)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DISC (disease control)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>low-dose cytarabine 20 mg/ m2 and /or mitoxantrone 10mg/m2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HAM</intervention_name>
    <description>High-dose cytarabine 1 - 3 g/m2 (days 1-3)/Mitoxantrone 20 mg/m2 (days3-5)</description>
    <arm_group_label>RIST(remission induction)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LDAC and/or Mitoxantrone</intervention_name>
    <description>Low-dose cytarabine 20 mg/m2 (days 1-10) and/ or mitoxantrone 10mg/m2 (max 3 doses)</description>
    <arm_group_label>DISC (disease control)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients of 18 to 75 years of age.

          -  Diagnosis of AML according to WHO criteria.

          -  Patient is fit for aggressive induction chemotherapy and transplantation by
             assessment of an experienced hematologist.

          -  HLA-identical sibling. or HLA-compatible (8/8) unrelated donor with completed
             confirmatory typing. or One potential HLA compatible (8/8) donor plus at least two
             back-up donors, who are at least 9/10 matches with &gt;90% probability for each of them.

          -  For the relapse stratum:

               -  First AML relapse, defined as ≥5% bone marrow blasts and / or extramedullary AML
                  manifestation.

          -  For the poor-responders stratum:

               -  If patient ≤60 years old: High risk AML according to ELN-criteria and ≥5% bone
                  marrow blasts after the first cycle of induction therapy.

               -  If patient &gt;60 years old: Non-favourable risk AML according to ELN-criteria and
                  ≥5% bone marrow blasts after the first cycle of induction therapy.

        Exclusion Criteria:

          -  Acute promyelocytic leukemia (APL).

          -  WBC count of ≥50 GPt/L at study inclusion.

          -  For patients in the poor-responder stratum the first cycle of induction therapy must
             not contain HDAC, defined as cytarabine at single-doses of ≥1g/ m2.

          -  Patient has received more than 80% of the tolerable cumulative anthracycline dose
             (see chapter 7.2. for definitions and worksheet for calculation).

          -  Severe organ dysfunction, .

          -  Uncontrolled infection at the time of enrollment.

          -  History of allogeneic transplantation.

          -  Manifestation of AML in the central nervous system.

          -  Pregnant or breast-feeding women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johannes Schetelig</last_name>
    <role>Study Chair</role>
    <affiliation>Universtitätsklinikum Dresden</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Raquel Palencia</last_name>
    <phone>49351210798</phone>
    <phone_ext>21</phone_ext>
    <email>palencia@dkms.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universitätsmedizin Mannheim III. Medizinische Klinik Hämatologie und Onkologie</name>
      <address>
        <city>Mannheim</city>
        <state>Baden-Württemberg</state>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michaela Hausmann</last_name>
    </contact>
    <investigator>
      <last_name>Stefan A. Klein, PD Dr med</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Robert-Bosch-Krankenhaus</name>
      <address>
        <city>Stuttgart</city>
        <state>Baden-Württemberg</state>
        <zip>70376</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Heidmann</last_name>
    </contact>
    <investigator>
      <last_name>Martin Kaufmann, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen Medizinische Klinik und Poliklinik Onkologie, Hämatologie, Rheumatologie und Pulmologie</name>
      <address>
        <city>Tübingen</city>
        <state>Baden-Württemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anja Junker</last_name>
    </contact>
    <investigator>
      <last_name>Wolfgang Bethge, Prof Dr Med</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Augsburg</name>
      <address>
        <city>Augsburg</city>
        <state>Bavaria</state>
        <zip>86156</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franziska Knieler</last_name>
    </contact>
    <contact_backup>
      <last_name>Silvia Söllner</last_name>
    </contact_backup>
    <investigator>
      <last_name>Christoph Schmid, PD Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen</name>
      <address>
        <city>Erlangen</city>
        <state>Bavaria</state>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrike Höfer</last_name>
    </contact>
    <contact_backup>
      <last_name>Evi Weiß</last_name>
    </contact_backup>
    <investigator>
      <last_name>Stefan Krause, Prof Dr med</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Nürnberg Nord Medizinische Klinik 5</name>
      <address>
        <city>Nürnberg</city>
        <state>Bavaria</state>
        <zip>90419</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karin Westphal</last_name>
    </contact>
    <investigator>
      <last_name>Kerstin Schäfer-Eckart, Dr Med</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Dresden</city>
        <state>Free State of Saxony</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johannes Schetelig, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt, Med. Klinik II - Hämatologie/Onkologie</name>
      <address>
        <city>Frankfurt am Main</city>
        <state>Hessen</state>
        <zip>60595</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wagner-Scherneck</last_name>
    </contact>
    <investigator>
      <last_name>Gesine Bug, PD Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster, KMT-Zentrum</name>
      <address>
        <city>Münster</city>
        <state>North Rhine-Westphalia</state>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vera Gordon</last_name>
    </contact>
    <contact_backup>
      <last_name>Birgit Mayerhoffer</last_name>
    </contact_backup>
    <investigator>
      <last_name>Matthias Stelljes, Prof Dr Med</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>III. Medizinische Klinik und Poliklinik Universitätsmedizin der Johannes Gutenberg-Universität Mainz</name>
      <address>
        <city>Mainz</city>
        <state>Rhineland-Palatinate</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christiane Schön</last_name>
    </contact>
    <contact_backup>
      <last_name>Andrea Schulz</last_name>
    </contact_backup>
    <investigator>
      <last_name>Eva Wagner, Dr Med</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Halle (Saale) Klinik für Innere Medizin IV Hämatologie/Onkologie/Hämostaseologie</name>
      <address>
        <city>Halle</city>
        <state>Saxony-Anhalt</state>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antje Kleinbauer</last_name>
    </contact>
    <investigator>
      <last_name>Lutz Peter Müller, Dr med habil</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 31, 2017</lastchanged_date>
  <firstreceived_date>May 28, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Mitoxantrone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
